Skip to main content
Caris Life Sciences10-Q: Customer concentration

Medicare accounted for 36.9% of molecular profiling services revenue in Q3 2026

Source: Autobound Signal API · 74 signals tracked for Caris Life Sciences · updated

Get Caris Life Sciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Caris Life Sciences this week? Use Autobound signals for carislifesciences.com.

What happened

Revenue from clinical cases covered by Medicare represented approximately 36.9% of molecular profiling services revenue for the three months ended September 30, 2026.

Source

SEC EDGARNov 4, 2026

Quarterly report (Form 10-Q)

Caris Life Sciences 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

Revenue from clinical cases for patients covered by Medicare represented approximately 36.9% and 39.4% of our molecular profiling services revenue for the three months ended September 30, 2026 and 2025, respectively.

sec.gov/Archives/edgar/data/2019410/000201941026000069/cai-20260930.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Customer concentration

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Nov 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
36.9% (share of molecular profiling services revenue from Medicare patients)

Details

CIK
2019410
Accession number
0002019410-26-000069
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Diversification strategy
Signal category
Market

Extraction

Confidence
High
Relevance
70%
Sentiment
Neutral
Detected
Nov 10, 2026
signal_type
sec-10q
signal_subtype
customerConcentration

Use this data

Get every 10-Q signal for Caris Life Sciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Caris Life Sciences this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/70f5130a-834e-4dad-92e6-ba1f6b8c37fb returns this record as JSON. POST /v1/companies/enrich returns every signal for carislifesciences.com.

{
  "signal_id": "70f5130a-834e-4dad-92e6-ba1f6b8c37fb",
  "signal_type": "sec-10q",
  "signal_subtype": "customerConcentration",
  "detected_at": "2026-11-10T08:02:40.406+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "detail": "Revenue from clinical cases covered by Medicare represented approximately 36.9% of molecular profiling services revenue for the three months ended September 30, 2026. This reveals substantial concentration in government reimbursement, creating potential opportunities for revenue cycle management and payer compliance solutions.",
    "metrics": {
      "pct": 0.369,
      "timeframe": "current_quarter",
      "pct_context": "share of molecular profiling services revenue from Medicare patients"
    },
    "quarter": "Q3",
    "summary": "Medicare accounted for 36.9% of molecular profiling services revenue in Q3 2026",
    "excerpts": "Revenue from clinical cases for patients covered by Medicare represented approximately 36.9% and 39.4% of our molecular profiling services revenue for the three months ended September 30, 2026 and 2025, respectively.",
    "relevance": 0.7,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/2019410/000201941026000069/cai-20260930.htm",
    "filing_date": "2026-11-04",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Diversification strategy",
    "signal_category": "market"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.